3Goessl C,Knispel H H.Fiedler U.et a1.Urodynamic effects of oral oxybutynin chlori cie in children with myelomeningocele and detrusor hyperreflexia.Urology,l998.51:94—98.
4Kuo HC. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology, 2005,66:94-98.
5Giannantoni A, Mearini E, Di Stasi SM, et al. New therapeutic options for refractory neurogenic detrusor overactivlty. Minerva Urol Nefrol,2004,56:79-87.
6Weese DL, Roskamp DA, Leach GE,et al. Intravesical oxybutynin chloride: experience with 42 patients.Urology, 1993,41:527-530.
7De Waehter S, Wyndaele JJ. Intravesical oxybutynin: a local anesthetic effect on bladder C afferents. J Urol,2003,169:1892-1895.
8Stewart WF, Van Rooyen JB, et al.Prevalence and burden of overactive bladder in the United States. World J Uroh 2003,20: 327-336.
9Temml C, Heldler S, Ponholzer A, et al. Prevalence of the overactive bladder syndrome by applying the International Continence Society definition.Eur Urol, 2005, 48:622-627.
10Homma Y, Yamaguehi O, Hayashi K,et al. An epidemiologieal survey of overactive bladder symptoms in Japan.BJU Int, 2005,96:1314-1318.
2Chaneellor MB,Oak R,Vasavada S.The overactive bladdersyndrome (OAR)and obesity,evidence of antimusearinic effi-cacy regardless of body Fllas S index at baseline.Urol,2009,181(4):676.
3Chapple CR,gaplan SA.Risk factors and comorbid conditions associated with lower urinary tract symptonls:EpiLUTS.BJU Int,2009,103(Suppl3):24-32.
4Coync KS,Sexton CC,Kopp ZS,et al.Rationale for the study methods and design of the epidemiology of lower urinary tract symptoms study.BJU Int,2009,104(3):348-351.
5Fletcher SO,Haverkom RM,Lee JJ,at al.Demographic and urodynamic factors associated with persistent OAB after prolapse repair.J Urol.2009,181(4):598.
